



## Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

October 12, 2022

### Six abstracts selected for presentation, including three oral presentations

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- [Entasis Therapeutics Holdings Inc.](#), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at [IDWeek 2022](#), the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.

Details of the presentations are as follows:

#### Oral Presentations:

**Title:** Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with *Acinetobacter baumannii-calcoaceticus* complex (ABC) infections

**Presenter:** David Altarac, MD, MPA

**Date and time:** Thursday, October 20, 2022, 1:45pm-3:00pm ET

**Session:** 78

**Title:** Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) *Acinetobacter baumannii-calcoaceticus* complex (ABC) infections

**Presenter:** Alita Miller, PhD

**Date and time:** Thursday, October 20, 2022, 1:45pm-3:00pm ET

**Session:** 78

**Title:** Population pharmacokinetic (PPK), pharmacokinetic/pharmacodynamic attainment (PTA), and clinical pharmacokinetic/pharmacodynamic (PK/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of *Acinetobacter baumannii-calcoaceticus* complex (ABC) infections

**Presenter:** Sujata Bhavnani, PharmD (Institute for Clinical Pharmacodynamics)

**Date and time:** Saturday, October 22, 2022, 1:45pm-3:00pm ET

**Session:** Late Breakers

#### Poster Presentations:

**Title:** Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with *Acinetobacter baumannii-calcoaceticus* complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)

**Presenter:** Drew Lewis, MD, MTM&H, FACP

**Poster #:** 675

**Date and time:** Thursday, October 20, 2022, 12:15pm-1:30pm ET

**Title:** Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant *Acinetobacter baumannii-calcoaceticus* complex (CRABC) infections

**Presenter:** Khurram Rana, PharmD

**Poster #:** 225

**Date and time:** Thursday, October 20, 2022, 12:15pm-1:30pm ET

**Title:** Characterization of colistin-resistant (COL-R) *Acinetobacter baumannii-calcoaceticus* complex (ABC) isolates from a recent global phase 3 trial (ATTACK)

**Presenter:** Sarah McLeod, PhD

**Poster #:** 518

**Date and time:** Thursday, October 20, 2022, 12:15pm-1:30pm ET

#### About Entasis Therapeutics Holdings Inc.

Entasis is a late-stage clinical biopharmaceutical company, and wholly owned subsidiary of Innoviva, Inc., is focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae* infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including *Pseudomonas*). For more information, visit [www.entasistx.com](http://www.entasistx.com).

#### About Innoviva

Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, "FF/VI"), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, "UMEC/VI") and, formerly, TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist ("LABA") Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GSK group of companies.

Innoviva strengthened its portfolio in the hospital and infectious disease space through the acquisition of Entasis Therapeutics Holdings Inc. and La Jolla Pharmaceutical Co. Its development pipeline includes potentially first- and best-in-class medicines for the treatment of multidrug-resistant bacteria, including lead asset SUL-DUR. The Company's commercial and marketed products include GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections (cIAIs).

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GSK group of companies.

#### **Cautionary Statement Regarding Forward Looking Statements**

*To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements regarding Innoviva's completion of the offering, the anticipated principal amount of securities sold, the final terms of the offering, Innoviva's anticipated use of proceeds, Innoviva's ability to repurchase the 2023 Notes and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, see the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 28, 2022, which is on file with the SEC and available on the SEC's website at [www.sec.gov](http://www.sec.gov). In addition to the risks described above and in Innoviva's other filings with the SEC, other unknown or unpredictable factors also could affect Innoviva's results. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.*

*Trademark reference: Innoviva and the Innoviva logo are registered trademarks or trademarks of Innoviva, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.*

#### **Company Contact**

Kyle Dow  
Entasis Therapeutics  
(781) 810-0114  
[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

#### **Media Contact**

Brett Whelan  
LifeSci Communications  
(215) 315 3143  
[bwhelan@lifescicomms.com](mailto:bwhelan@lifescicomms.com)



Source: Entasis Therapeutics Holdings Inc.